In tro d u c tio n . The cu rre n t pharm aceuti cal analys is has got more emphas is to sati sfy o u r query for better understanding o f p hys i cochemi cal propert ies o f p harmaceuti cal compounds, by the use of advanced instrumental methods. It also plays an important part for qual ity assurance o f pharmaceuti cal product throughout the shelf l ife. The pharmaceuti cal industry i s under increased scrut iny to constra i n costs a nd yet consistently del iver to market safe, e fficac ious products that fulfi ll med ical needs. As a part o f t h is, drug a n alys is also plays an i mportant role. Standard analyti cal procedure for newer drugs or formati on may not be ava ilable in Pharmacopoe i a; it is essenti al to develop new analyti cal methods wh i ch are accurate, prec ise, specific, linear, s imple and rap id. Desloratadi ne (8-chloro-6,11-d i hydro-11 -(4-p iperdinyl idene)-5H-benzo [5,6]cyclohepta[1,2-b]pyri dine) is a med i c i ne used to treat allergies. It is marketed under several trade names such a s N eoClarityn, Claramax, Clari nex, Edem, Lar inex, Aeri us, Dazit, Azomyr, Deselex and Delot. It is an active metabol ite of loratadine (second generati on), wh ich is also on the pharmaceuti cal market. Desloratadine is a tricycl i c a nti h istam ine (t h ird generation), wh i ch has a selective and peri pheral H1-antagon i st act i on. It is an antagon ist at h istam ine H1 receptors, and an antagon i st at all subtypes of the muscari n ic acetylchol i ne receptors. Desloratadine is a non-sedating, long-acting histam ine antagonist with selective peri pheral H1-receptor antagon ist activity. After oral adm inistrati on, desloratadi ne selectively blocks peripheral histam ine H1-receptors, because the substance is e xcluded from e ntry to the central nervous system. It has a long-lasting effect and in moderate and low doses, does not cause drows iness because it does not read ily enter the central nervous system. Unl ike other anti h i stam ines, desloratadine is also effective in rel ieving nasal congestion, parti cularly in pati ents with allerg ic rh i n iti s. Analys is o f d e s loratad ine is not descr ibed in Pharmacope i a, that's why develop ment and val idati on of methods for determ inati on of desloratadine in med i c ines was our ma i n a im [1]. We proposed and developed a method for spectrophotometri c a nd chromatograph i c identifi cati on o f d e s lora tadine in med i c i nes.
absorpti on spectrophotometry and th in layer chro matography.
Materials and methods of research. The objects o f the study were tablets tablets «Aeri us», tablets «Deslor», tablets «Aeriallerg», Pharmacopoe ial stan dard sample SPU desloratadine (certificate number 11/1-3187 of 08/13/14), purchased by the State Enterpri se «Ukra i n i an Research Pharmacopoei al Center Qual ity of drugs."
Analytical equipment: UV spectrophotom eter Lambda 25, Scales AVT-120-5D, measuri ng vessel glass and reagents that meet the SPU requ irements. TLC test was carri ed out us ing S i l i ca gel, chromato graph i c plates 60 F254 «Merck» (Germany) and «Sorbf l» (Russ a).
In develop ing the techn i que o f identifi cati on data as part of de s loratadine med i c i nes was chosen by UVspectrophotometry a nd TLC.
Results and discussion. We had previously stud i ed the behavi or o f d e s loratadine in the UV spectra us ing in different solvents (ethanol, water R, 0.1 mol/l soluti on of hydrochlori c ac i d). The behavior of desloratadine in the UV spectrum in different solvents showed that all drugs have character i st i c absorpti on bands i n the wavelength range (2 2 0 -3 6 0 nm). Absorpti on maxi mum of desloratadine: in ethanolwhen 244±2 nm; 0.1 M soluti on of hydrochlori c ac i d at 280±2 nm; in water -at 244±2 nm and 273±2 nm ( fig. 1 ). It makes it poss ible for the use of UV-spectrophotometry for analys i s of desloratadi ne in med ic i nes [2] .
We had i nvestigated various mob i le phases (solvent system) in order to identify the o pti mal cho ice of desloratadine investi gat ion by TLC in med ic ines. The factors of mob i l ity in the stud ied systems of deslora tadine solvents, are l isted in table 1, 2.
In order to develop methods of identifi cati on of desloratadine in d ifferent solvent system, we investigated the sens itivity of detecti on desloratadine. The value detection l i m it desloratadine and selection of opti mal developers us ing different mob ile phases are g iven i n table 1-2. We found that desloratadi ne identifi cati on by TLC us ing a sens itive of all investigated solvents. Therefore, to i dentify a part deslorata dine tablets can be used TLC method. Establ i shed that the most opti mal Rf observed us ing rmob i le phases:
Огляди літератури, оригінальні дослідження, погляд на проблему dіoxane-benzene-ammon і а (25 %) (7: 12: 1) and However, the express solvent system n-butanol-aceti c n-butanol-acet і c ac і d-water (1: 1: 1). The detect ion ac і d-water (1: 1: 1) yi elds a solvent system d ioxanelimit desloratad іпє іп these systems і s 0.2-0.4 mg. benzene-ammon і a (25 %) (7: 12: 1). Thus, identificati on o f d e s loratadine med ic ines we offer TLC-method us i ng solvent system d i oxanebenzene-ammon i a (25 %) (7 : 12 : 1) and stati onary phase -plate «Merch».
The a n alys is cons i dered probable, though the test requ i rements «Check suitabi l ity chromatograph ic system».
Checking the suitability o f the chromatographic system. Chromatograph ic system is considered appropr ate when: -The chromatogram obta i ned with reference solut ion i s a clearly v i s ible spot; -Rf pri nc i pal spot in the chromatogram o bta i ned with reference solution to be about 0.6.
Investigation solutions from tablets «Aerius», tablets «Deslor», tablets «Aeriallerg». To sample powder tablets or powder, equ ivalent to 0.01 g desloratadine, add 5.0 ml of ethanol R and d ilute with ethanol R to 10.0 ml, m ix and fi lter.
Reference solution. 0.01 g Pharmacopoeialstandard sample SPU of desloratadine dissolved in ethanolR and d i lute with the same solvent to 10.0 ml.
Mob ile phase: di oxane-benzene-ammonia (25 %) (7 : 12 : 1).
Samples that are a pplied: 50 mg, a ppl ied the test soluti on a nd investi gati on solut ions. We previ ously stud ied the behav ior of placebo tablets i n terms o f methods o f identifi cati on o f d e s lora tadine. It was establ ished that the exc ip i ents are part of p i lls and do not affect the sens itivity and spec ifi c ity of desloratadine detecti on. According to the S PU a nd Note for gui dance on val i dati on of analytical proce dures: text and methodology (CPMP/ICH/381/95) to test the «Identifi cat ion» m ust be val i dated, to determ ine such characteri sti cs a s spec ifi c ity a nd suitab i l ity o f t he chromatograph i c system.
To investi gate the spec ifi c ity, it i s necessary to confi rm the selected mobi l ity o f d e sloratadine system to ensure proper Rf stab il ity of soluti ons in ti me. The maxi mum difference of Rf values i n the same plate (for two seri es o f p lates) m ust not e xceed the value o f O. 02. Ori g i nally, plates were tested according to the requ irements of SPU o n chromatograph i c resolut i on.
When checking for the stabi l ity of the soluti on at the ti me we started chromatography of d esloratadine freshly prepared test soluti on susta i ned, over ti me for 30 m in. Visual assessment of spots on the size and intens ity of sta i n ing confi rms that they clearly appear as freshly cooked a nd seasoned in ti me soluti ons (for plates of different seri es). The solutions were stable over ti me and new areas, had been i dentifi ed.
Thus, we explored the val i dati on characteristi csspec ific ity a nd su itab il ity o f the chromatograph ic system
